Engagement of CD22 on B cells with the monoclonal antibody epratuzumab stimulates the phosphorylation of upstream inhibitory signals of the B cell receptor

Journal of Cell Communication and Signaling

Volumn 10, Issue 2, 2016, Pages 143-151

  Lumb, Simon ^a   Fleischer, Sarah J ^b   Wiedemann, Annika ^b   Daridon, Capucine ^b,c   Maloney, Alison ^a   Shock, Anthony ^a   Dörner, Thomas ^b  

^a UCB PHARMA   (Belgium)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c NONE   (France)

Author keywords

B cell receptor; CD22; CD32B; Epratuzumab; Phosphorylation

Indexed keywords

EID: 84964499378     PISSN: 18739601     EISSN: 1873961X     Source Type: Journal    
DOI: 10.1007/s12079-016-0322-1     Document Type: Article

References (29)

1. 2+ signalling. EMBO J 30:1621–1633
2. Carnahan J, Wang P, Kendall R, Chen C, Hu S, Boone T, Juan T, Talvenheimo J, Montestruque S, Sun J (2003) Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin Cancer Res 9:3982s–3990s
3. Catalán D, Aravena O, Sabugo F, Wumann P, Soto L, Kalergis AM, Cuchacovich M, Aguillón JC (2010) B cells from rheumatoid arthritis patients show important alterations in the expression of CD86 and FcγRIIb, which are modulated by anti-tumor necrosis factor therapy. Arth Res Ther 12:R68
4. Coggeshall KM (1998) Inhibitory signals by B cell FcγRIIb. Curr Opin Immunol 10:306–312
5. Dörner T, Shock A, Smith KG (2012) CD22 and autoimmune disease. Int Revs Immunol 31:363–378
6. Dörner T, Shock A, Goldenberg DM, Lipsky PE (2015) The mechanistic impact of CD22 engagement with epratuzumab on B cell function: implications for the treatment of systemic lupus erythematosus. Autoimmun Rev 14:1079–1086
7. Fleischer V, Sieber J, Fleischer SJ, Shock A, Heine G, Daridon C, Doerner T (2015a) Epratuzumab inhibits the production of proinflammatory but not regulatory cytokines by B cells from healthy donors and SLE-patients. Arth Res Ther 17:185
8. Fleischer SJ, Daridon C, Fleischer V, Lipsky PE, Dörner T (2015b) Enhanced tyrosine phosphatase activity underlies dysregulated B-cell receptor signaling and promotes survival of human lupus B-cells. Arthritis Rheumatol Accept Article. doi:10.1002/art.39559
9. Goldenberg DM (2006) Epratuzumab in the therapy of oncological and immunological diseases. Expert Rev Anticancer Ther 6:1341–1353
10. Grimaldi CM, Hicks R, Diamond B (2005) B cell selection and susceptibility to autoimmunity. J Immunol 174:1775–1781
11. Isnardi I, Lesourne R, Bruhns P, Fridman WH, Cambier JC, Daëron M (2004) Two distinct tyrosine-based motifs enable the inhibitory receptor FcRIIB to cooperatively recruit the inositol phosphatases SHIP1/2 and the adapters Grb2/Grap. J Biol Chem 279:51931–51938
12. Jacobi AM, Goldenberg DM, Hiepe F, Radbruch A, Burmester GR, Dörner T (2008) Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls. Ann Rheum Dis 67:450–457
13. Jang IK, Zhang J, Gu H (2009) Grb2, a simple adapter with complex roles in lymphocyte development, function, and signaling. Immunol Rev 232:150–159
14. Keren Z, Melamed D (2005) Antigen receptor signaling competence and the determination of B cell fate in B-lymphopoiesis. Histol Histopathol 20:187–196
15. Mackay M, Stanevsky A, Wang T, Aranow C, Li M, Koenig S, Ravetch JV, Diamond B (2006) Selective dysregulation of the FcγRIIB receptor on memory B cells in SLE. J Exp Med 203:2157–2164
16. Maloney A, Hotson D, Rapecki S, Fossati G, Lumb S, Rosen D, Putta S, Wale N, Spellmeyer D, Cesano A, Hawtin R, Shock A (2014) Epratuzumab induces broad inhibition of B cell receptor proximal signaling but has opposing effects on distal signaling in B cell subsets: a profile of effects on functional immune signaling by single cell network profiling. Arthritis Rheum 66:S1255
17. Muta T, Kurosaki T, Misulovin Z, Sanchez M, Nussenzweig MC, Ravetch JV (1994) A 13-amino-acid motif in the cytoplasmic domain of Fc gamma RIIB modulates B-cell receptor signalling. Nature 368:70–73
18. Neumann K, Oellerich T, Heine I, Urlaub H, Engelke M (2011) Fc gamma receptor IIb modulates the molecular Grb2 interaction network in activated B cells. Cell Signal 23:893–900
19. Nitschke L (2005) The role of CD22 and other inhibitory co-receptors in B-cell activation. Curr Opin Immunol 17:290–297
20. Otipoby KL, Draves KE, Clark EA (2001) CD22 regulates B cell receptor-mediated signals via two domains that independently recruit Grb2 and SHP-1. J Biol Chem 276:44315–44322
21. Poe JC, Fujimoto M, Jansen PJ, Miller AS, Tedder TF (2000) CD22 Forms a quaternary complex with SHIP, Grb2, and Shc: a pathway for regulation of B lymphocyte antigen receptor-induced calcium flux. J Biol Chem 275:17420–17427
22. Qu Z, Goldenberg DM, Cardillo TM, Shi V, Hansen HJ, Chang C-H (2008) Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action. Blood 111:2211–2219
23. Ravetch JV, Bolland S (2001) IgG Fc receptors. Ann Rev Immunol 19:275–290
24. Rossi EA, Goldenberg DM, Michel R, Rossi DL, Wallace DJ, Chang C-H (2013) Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab. Blood 122:3020–3029
25. Saxon A, Feldhaus J, Robins RA (1976) Single step separation of human T and B cells using AET treated SRBC rosettes. J Immunol Methods 12:285–288
26. Shock A, Kilgallen B, Koetse W, Stach C, Bongardt S, Galateanu C (2014) Pharmacodynamic effects of the CD22-targeted monoclonal antibody epratuzumab on B cells in patients with systemic lupus erythematosus. Arthritis Rheum 66:S856
27. Sieger N, Fleischer S, Mei H, Reiter K, Shock A, Burmester G, Daridon C, Dörner T (2013) CD22 ligation inhibits downstream B cell receptor signaling and Ca2+ flux upon activation. Arthritis Rheum 65:770–779
28. Tsubata T (2012) Role of inhibitory BCR co-receptors in immunity. Infect Disord Drug Targets 12:181–190
29. Veri M-C, Burke S, Huang L, Li H, Gorlatov S, Tuaillon N, Rainey GJ, Ciccarone V, Zhang T, Shah K, Jin L, Ning L, Minor T, Moore PA, Koenig S, Hohnson S, Bonvini E (2010) Therapeutic control of B cell activation via recruitment of Fcγ receptor IIb (CD32B) inhibitory function with a novel bispecific antibody scaffold. Arthritis Rheum 62:1933–1943